Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement
Critère d'inclusion
- Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1,
- or ALK Gene Rearrangements